Organon & Co. Other Comprehensive Income (Loss), Net of Tax
Organon & Co. (OGN) reported Other Comprehensive Income (Loss), Net of Tax of -$9.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-31
- Organon & Co. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$9.00M, a 120.00% decline year-over-year.
- Organon & Co. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$12.00M, a 137.50% decline year-over-year.
- Organon & Co. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $47.00M.
- Organon & Co. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$2.00M, a 104.88% decline year-over-year.
- Organon & Co. other comprehensive income (loss), net of tax for fiscal 2025 was $122.00M.
- Organon & Co. other comprehensive income (loss), net of tax for fiscal 2024 was -$108.00M, a 569.57% decline from fiscal 2023.
- Organon & Co. other comprehensive income (loss), net of tax for fiscal 2023 was $23.00M.
- Organon & Co. other comprehensive income (loss), net of tax for fiscal 2022 was -$51.00M, a 152.04% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.00M 10-Q · filed 2026-07-31 | -$21.00M 10-Q · filed 2026-07-31 | $26.00M derived: sum of 3 quarters · filed 2026-07-31 | $24.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$12.00M 10-Q · filed 2026-05-04 | $35.00M derived: sum of 2 quarters · filed 2026-05-04 | $33.00M derived: sum of 3 quarters · filed 2026-05-04 | $78.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $45.00M derived: sum of 2 quarters · filed 2026-02-24 | $90.00M derived: sum of 3 quarters · filed 2026-07-31 | $122.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$2.00M 10-Q · filed 2025-11-10 | $43.00M derived: sum of 2 quarters · filed 2026-07-31 | $75.00M 10-Q · filed 2025-11-10 | -$3.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $45.00M 10-Q · filed 2026-07-31 | $77.00M 10-Q · filed 2026-07-31 | -$1.00M derived: sum of 3 quarters · filed 2026-07-31 | $40.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $32.00M 10-Q · filed 2026-05-04 | -$46.00M derived: sum of 2 quarters · filed 2026-05-04 | -$5.00M derived: sum of 3 quarters · filed 2026-05-04 | -$40.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$78.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$37.00M derived: sum of 2 quarters · filed 2026-02-24 | -$72.00M derived: sum of 3 quarters · filed 2026-02-24 | -$108.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $41.00M 10-Q · filed 2025-11-10 | $6.00M derived: sum of 2 quarters · filed 2025-11-10 | -$30.00M 10-Q · filed 2025-11-10 | $5.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$35.00M 10-Q · filed 2025-08-06 | -$71.00M 10-Q · filed 2025-08-06 | -$36.00M derived: sum of 3 quarters · filed 2026-02-24 | -$79.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$36.00M 10-Q · filed 2025-05-02 | -$1.00M derived: sum of 2 quarters · filed 2026-02-24 | -$44.00M derived: sum of 3 quarters · filed 2026-02-24 | -$43.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$8.00M derived: sum of 2 quarters · filed 2026-02-24 | -$7.00M derived: sum of 3 quarters · filed 2026-02-24 | $23.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$43.00M 10-Q · filed 2024-11-01 | -$42.00M derived: sum of 2 quarters · filed 2024-11-01 | -$12.00M 10-Q · filed 2024-11-01 | $110.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $1.00M 10-Q · filed 2024-08-07 | $31.00M 10-Q · filed 2024-08-07 | $153.00M derived: sum of 3 quarters · filed 2025-11-10 | $56.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $30.00M 10-Q · filed 2024-05-03 | $152.00M derived: sum of 2 quarters · filed 2025-11-10 | $55.00M derived: sum of 3 quarters · filed 2025-11-10 | -$5.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $122.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $25.00M derived: sum of 2 quarters · filed 2025-11-10 | -$35.00M derived: sum of 3 quarters · filed 2025-11-10 | -$51.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | -$97.00M 10-Q · filed 2023-11-03 | -$157.00M derived: sum of 2 quarters · filed 2023-11-03 | -$173.00M 10-Q · filed 2023-11-03 | -$193.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$60.00M 10-Q · filed 2023-08-09 | -$76.00M 10-Q · filed 2023-08-09 | -$96.00M derived: sum of 3 quarters · filed 2024-02-26 | -$122.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$16.00M 10-Q · filed 2023-05-05 | -$36.00M derived: sum of 2 quarters · filed 2024-02-26 | -$62.00M derived: sum of 3 quarters · filed 2024-02-26 | $150.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$46.00M derived: sum of 2 quarters · filed 2024-02-26 | $166.00M derived: sum of 3 quarters · filed 2024-02-26 | $98.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$26.00M 10-Q · filed 2022-11-04 | $186.00M derived: sum of 2 quarters · filed 2022-11-04 | $118.00M 10-Q · filed 2022-11-04 | $23.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $212.00M 10-Q · filed 2022-08-05 | $144.00M 10-Q · filed 2022-08-05 | $49.00M derived: sum of 3 quarters · filed 2023-02-27 | $93.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$68.00M 10-Q · filed 2022-05-06 | -$163.00M derived: sum of 2 quarters · filed 2023-02-27 | -$119.00M derived: sum of 3 quarters · filed 2023-02-27 | -$91.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$95.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$51.00M derived: sum of 2 quarters · filed 2023-02-27 | -$23.00M derived: sum of 3 quarters · filed 2023-02-27 | -$173.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $44.00M 10-Q · filed 2021-11-12 | $72.00M derived: sum of 2 quarters · filed 2021-11-12 | -$78.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $28.00M 10-Q · filed 2021-08-16 | -$122.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$150.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | -$6.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |